AV513

AV513 is a hemostatic botanical drug candidate consisting of a specific, selected fucoidan—a sulfated polysaccharide derived from seaweed. Originally developed by Avigen and later acquired by Baxter Healthcare in 2008, AV513 was designed to treat bleeding disorders such as hemophilia A and hemophilia B. Its mechanism of action involves the inhibition of tissue factor pathway inhibitor (TFPI), which reduces natural anti-coagulation and accelerates the initiation of blood clots at local bleeding sites. AV513 was investigated for both oral and subcutaneous administration, showing potential as either a standalone therapy or an adjunctive agent to enhance the efficacy of Factor VIII or Factor IX replacement therapies. The compound was selected for its minimal anticoagulant activity compared to other fucoidans, focusing its effect on pro-coagulant pathways.

Other names

fucoidan